Literature DB >> 16754430

Strategies to minimize risks and exploitation in phase one trials on healthy subjects.

Adil E Shamoo1, David B Resnik.   

Abstract

Most of the literature on phase one trials has focused on ethical and safety issues in research on patients with advanced cancer, but this article focuses on healthy, adult subjects. The article makes six specific recommendations for protecting the rights and welfare of healthy subjects in phase one trials: 1) because phase one trials are short in duration (usually 1 to 3 months), researchers should gather more data on the short-term and long-term risks of participation in phase one studies by healthy subjects; 2) researchers should develop strict inclusion/exclusion criteria that exclude unhealthy or vulnerable subjects, such as decisionally impaired people, in phase one studies; 3) subjects should not participate in more than one phase one study at the same time and should wait at least 30 days between participating in different studies; 4) researchers should develop a database to keep track of phase one participants; 5) subjects should be guaranteed a minimum wage equivalent to the equivalent type of unskilled labor, but there should be no upper limits on wages; and 6) subjects should be allowed to engage in collective bargaining with research sponsors.

Entities:  

Mesh:

Year:  2006        PMID: 16754430      PMCID: PMC3943957          DOI: 10.1080/15265160600686281

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


  37 in total

1.  What's the price of a research subject? Approaches to payment for research participation.

Authors:  N Dickert; C Grady
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

2.  What makes clinical research ethical?

Authors:  E J Emanuel; D Wendler; C Grady
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

3.  Phase I cancer trials. A collusion of misunderstanding.

Authors:  M Miller
Journal:  Hastings Cent Rep       Date:  2000 Jul-Aug       Impact factor: 2.683

4.  Swallowing bitter pills for pay: trials of human guinea pigs.

Authors:  David J Morrow
Journal:  N Y Times Web       Date:  1996-09-29

5.  Inducement in research.

Authors:  Martin Wilkinson; Andrew Moore
Journal:  Bioethics       Date:  1997-10       Impact factor: 1.898

Review 6.  The standard of disclosure in human subject experimentation.

Authors:  K Morin
Journal:  J Leg Med       Date:  1998-06

7.  Children as research subjects: a dilemma.

Authors:  L M Kopelman
Journal:  J Med Philos       Date:  2000-12

8.  Paying people to participate in research: why not? A response to Wilkinson and Moore.

Authors:  Paul McNeill
Journal:  Bioethics       Date:  1997-10       Impact factor: 1.898

9.  Perceptions of cancer patients and their physicians involved in phase I trials.

Authors:  C Daugherty; M J Ratain; E Grochowski; C Stocking; E Kodish; R Mick; M Siegler
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Pesticide testing on human subjects: weighing benefits and risks.

Authors:  David B Resnik; Christopher Portier
Journal:  Environ Health Perspect       Date:  2005-07       Impact factor: 9.031

View more
  24 in total

1.  Ethical issues in clinical trials involving nanomedicine.

Authors:  David B Resnik; Sally S Tinkle
Journal:  Contemp Clin Trials       Date:  2006-11-17       Impact factor: 2.226

2.  Randomized controlled trials in environmental health research: ethical issues.

Authors:  David B Resnik
Journal:  J Environ Health       Date:  2008 Jan-Feb       Impact factor: 1.179

3.  The myth of equipoise in phase 1 clinical trials.

Authors:  Adil E Shamoo
Journal:  Medscape J Med       Date:  2008-11-05

4.  Rethinking the vulnerability of minority populations in research.

Authors:  Wendy Rogers; Margaret Meek Lange
Journal:  Am J Public Health       Date:  2013-10-17       Impact factor: 9.308

5.  Intentional exposure studies of environmental agents on human subjects: assessing benefits and risks.

Authors:  David B Resnik
Journal:  Account Res       Date:  2007 Jan-Mar       Impact factor: 2.622

6.  Subversive subjects: rule-breaking and deception in clinical trials.

Authors:  Rebecca Dresser
Journal:  J Law Med Ethics       Date:  2013       Impact factor: 1.718

7.  Participants' responsibilities in clinical research.

Authors:  David B Resnik; Elizabeth Ness
Journal:  J Med Ethics       Date:  2012-07-19       Impact factor: 2.903

8.  Social Benefits of Human Subjects Research.

Authors:  David B Resnik
Journal:  J Clin Res Best Pract       Date:  2008-11-01

9.  Environmental Health Research Involving Human Subjects: Ethical Issues.

Authors:  David B Resnik
Journal:  Environ Health Insights       Date:  2008-07-14

Review 10.  The clinical investigator-subject relationship: a contextual approach.

Authors:  David B Resnik
Journal:  Philos Ethics Humanit Med       Date:  2009-12-03       Impact factor: 2.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.